

JENKINS
WILSON
TAYLOR
& HUNT

patent attorneys

January 12, 2007



RICHARD E. JENKINS

JEFFREY L. WILSON

ARLES A. TAYLOR, JR.

GREGORY A. HUNT

BENTLEY J. OLIVE

*CHRIS PERKINS, PH.D.

**JAMES DALY IV, PH.D.

P. ASHLEY DARDEN

DAVID M. SIGMON

WESLEY A. SHEFFIELD

SCOTT C. MAYHEW

***KIRBY A. TURNER

PATENT AGENT
JAY KLINCK

TECHNICAL SPECIALIST
AMY ODENBAUGH, PH.D.

*LICENSED ONLY IN CA

**LICENSED ONLY IN KY

***LICENSED ONLY IN GA

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on January 12, 2007.

Oksana Buynitzky

Date of Signature: January 12, 2007

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Re: U.S. Patent Application Serial No. 10/529,071 for
TARGETED TUMOR THERAPY BY USE OF RECOMBINANT
ADENOVIRUS VECTORS THAT SELECTIVELY REPLICATE IN
HYPOXIC REGIONS OF TUMORS
Our Ref. No. 180/156 PCT/US

Sir:

Please find enclosed in connection with the subject U.S. patent application the following documents:

1. Information Disclosure Statement (2 pages);
2. Form PTO-1449 (2 pages);
3. Copies of cited references (5 references); and
4. A return-receipt postcard to be returned to us with the U.S. Patent and Trademark Office filing stamp thereon.

Although no fee is believed to be due, the Commissioner is hereby authorized to charge any fees associated with the filing of this correspondence to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS, WILSON, TAYLOR & HUNT, P.A.

Arles A. Taylor, Jr.
Registration No. 39,395

AAT/omb

Enclosures

Customer No. 25297

tel 919.493.8000
fax 919.419.0383

Jenkins, Wilson, Taylor & Hunt, P.A.
JenkinsWilson.com

University Tower, Suite 1200 | 3100 Tower Boulevard | Durham, North Carolina 27707

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on January 12, 2007.

PATENT



Okla Buynitzky
Date of signature

January 12, 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Li et al.

Group Art Unit: 1632

Serial No.: 10/529,071

Examiner: Not assigned

Filed: March 24, 2005

Docket No.: 180/156 PCT/US

For: TARGETED TUMOR THERAPY BY USE OF RECOMBINANT ADENOVIRUS
VECTORS THAT SELECTIVELY REPLICATE IN HYPOXIC REGIONS OF
TUMORS

INFORMATION DISCLOSURE STATEMENT

(After First Office Action but Within 3 Months of Communication from Foreign Patent Office)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97, and 1.98, applicants' undersigned attorney brings to the attention of the Patent and Trademark Office the documents listed on the attached form PTO-1449. Copies of the references as well as Form PTO-1449 are attached hereto. This is not to be construed as a representation that a search has been made or that a reference is relevant merely because cited.

No fee under 37 C.F.R. Section 1.17(p) is due as the undersigned hereby certifies that each item of information contained in this statement was cited in a communication

from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

Early passage of the subject application to issue is earnestly solicited.


Although it is believed that no fee is due, the Commissioner is hereby authorized to charge any fees associated with the filing of this Information Disclosure Statement to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS, WILSON, TAYLOR & HUNT, P.A.

Date: January 12, 2007

By:



Arles A. Taylor, Jr.
Registration No. 39,395

REJ/gwc

Enclosures

Customer No. 25297

180/156 PCT/US



FORM PTO-1009 U.S. Department of Commerce Patent and Trademark Office List of Documents Cited by Applicant	Application No.:	10/529,071
	Filing Date:	March 24, 2005
	First Named Inventor:	Li et al.
	Group:	1632
	Examiner:	Not assigned
Attorney Docket No.:		180/156 PCT/US

U.S. PATENT DOCUMENTS

Examiner Initial	Cite No.	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, where relevant passages or relevant figures appear

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number (country code, no., kind code (if known))	Publication Date	Name of Patentee or Applicant	Pages, columns, lines where relevant passages appear	T

OTHER DOCUMENTS

Examiner Initials	Cite No.	Include Author (in CAPITAL LETTERS), Title, Journal, Date, Pertinent Pages, Etc.	T
	A	Koshikawa et al. <i>Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumor cells.</i> <i>Cancer Research</i> , Vol. 60, (2000), pp.2936-2941	
	B	Griffiths et al. <i>The macrophage – a novel system to deliver gene therapy to pathological hypoxia.</i> <i>Gene Therapy</i> , Vol. 7, (2000), pp.255-262	
	C	Kurihara et al. <i>Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen.</i> <i>The Journal of Clinical Investigation</i> , Vol. 106, no. 6, (2000), pp.763-771	

	D	Kruyt et al. <i>Toward a new generation of conditionally replicating adenoviruses: pairing tumor selectivity with maximal oncolysis.</i> <i>Human Gene Therapy</i> , Vol. 13, (2002), pp.485-495	
	E	Supplementary Partial European Search Report corresponding to EP application No. EP 03799374 dated November 24, 2006.	

EXAMINER _____ DATE CONSIDERED _____

*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.